61220-35-7

Usage

Uses

Used in Pharmaceutical Industry:
Urea, [1-(phenylmethyl)-4-piperidinyl]is used as a pharmacological ingredient for its potential therapeutic applications, particularly in the treatment of central nervous system disorders. Its unique structure allows it to serve as a promising drug target, contributing to the development of new medications.
Used in Cosmetic Industry:
In the cosmetic sector, Urea, [1-(phenylmethyl)-4-piperidinyl]is utilized for its aromatic properties, enhancing the fragrance and sensory experience of various products. Its presence in cosmetic formulations can also contribute to the overall effectiveness of the product, thanks to its potential pharmacological properties.

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 76713-26-3 4-(Phenylcarbonylaminocarbonyl)amino-1-benzyl-piperidine 

Downstream Products

• 164393-09-3 1-(1-benzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one 
• 164393-32-2 1,3-dihydro-5-methyl-4-phenyl-1-(4-piperidinyl)-2H-imidazol-2-one 
• 164393-22-0 1-[1-(3-cyanobenzyl)piperidin-4-yl]-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one 

Relevant academic research and scientific papers

1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol- 2-one: A selective high-affinity antagonist for the human dopamine D4 receptor with excellent selectivity over ion channels

After the requirement of pseudocycle formation in the ureas 3 and 7 for hD4 binding and selectivity was confirmed, structural hybridization with the known hD4 ligand 2 led to the design and identification of the lead 4-(2- oxo-1,3-dihydroimidazol-2-yl)piperidine 8. Optimization studies were carried out on 8 with the aim of achieving 1000-fold selectivity for hD4 over all other receptors while retaining the good pharmacokinetic properties of the lead. After initial preparation of 8 as a minor component in a low-yielding reaction, a novel and regioselective 'four-step/one-pot' procedure was developed which proved to be applicable to rapid investigation of the SAR of the 1,3-dihydroimidazol-2-one ring. Various changes to substituents attached to the 3-, 4-, or 5-position of the 1,3-dihydroimidazol-2-one core of 8 did not significantly improve selectivity for hD4 over hD2 and hD3. Greater selectivity (> 1000-fold) was ultimately achieved by meta substitution of the benzyl group of 8 with various substituents. Compounds 28, 31, and 32 all possess the required selectivity for hD4 over the other dopamine subtypes, but only 32 has > 1000-fold selectivity over all the key counterscreens we tested against. Compound 32 is an antagonist at hD4 and has a good pharmacokinetic profile in the rat, with excellent estimated in vivo receptor occupancy, thus making it a potentially useful pharmacological tool to investigate the role of the D4 receptor.

IMIDAZOLONE AND OXAZOLONE DERIVATIVES AS DOPAMINE ANTAGONISTS

A class of imidazolone and oxazolone derivatives of Structure I, STR1 wherein X represents oxygen or N--R 1 ; Q represents a substituted five-, six-or seven-membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole hetero